Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct 31;16(1):e57897.
doi: 10.5812/ijem.57897. eCollection 2018 Jan.

Thrombosis in Thyroid Cancer

Arash Ordookhani  1 , Abbas Motazedi  1 , Kenneth D Burman  2
Affiliations
Review

Thrombosis in Thyroid Cancer

Arash Ordookhani et al. Int J Endocrinol Metab. .

Abstract

Background: The number of studies on venous thromboembolism (VTE) and thyroid cancer is very scarce and existing data are contradictory. This paper reviews VTE in thyroid cancer.

Methods: The following words were used for a comprehensive literature review using MEDLINE database: Blood coagulation factors; thyroid hormones; blood coagulation tests; venous thromboembolism; receptors thyroid hormone; hemostasis; fibrinolysis; bleeding; blood coagulation disorders; thyroid neoplasms; Thyroid cancer, papillary; Thyroid cancer, follicular; Thyroid carcinoma, anaplastic; Thyroid cancer, Hurthle cell; Familial medullary thyroid carcinoma; venous thrombosis; Pulmonary embolism; Blood coagulation factors. The studies, which include any changes in hemostasis and thyroid cancer were included and reviewed.

Results: Although few studies have shown a possible increase in VTE occurrence in thyroid cancer in patients ≥ 60 years old and in proximity to cancer diagnosis, other studies could not find any difference compared to general population. New thyroid cancer classification excluding common subtype(s) with benign nature, may affect the results of the future studies on association of VTE and thyroid cancer.

Conclusions: Prospective studies on the occurrence of VTE in various types and severities of thyroid cancer and in different age groups are warranted, as the results would affect clinical practice on the necessity of usage of anticoagulants in some thyroid cancer groups.

Keywords: Blood Coagulation Factors; Fibrinolysis; Receptor, Thyroid Hormone; Thyroid Hormones; Thyroid Neoplasms; Venous Thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:None to declare.

Figures

Figure 1.
Figure 1.. Flowchart of Assessment and Selection of the Studies Used in This Review*
See this image and copyright information in PMC

References

    1. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839–47. doi: 10.1200/JCO.2009.22.3271. - DOI - PMC - PubMed
    1. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285–91. - PubMed
    1. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002;87(6):1076–7. - PubMed
    1. Heit JA. Cancer and venous thromboembolism: scope of the problem. Cancer Control. 2005;12 Suppl 1:5–10. - PubMed
    1. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275. doi: 10.1371/journal.pmed.1001275. - DOI - PMC - PubMed

LinkOut - more resources